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Introduction: The mechanism by which hypertension is maintained in renovascular hypertension remains poorly defined.
Because plasma angiotensin II does not correlate with blood pressure in RVH, we postulated that activation of
tissue-specific autocrine-paracrine renin-angiotensin systems may upregulate local production of angiotensin II and
maintain hypertension in chronic RVH.
Methods: RVH was induced with a two-kidney one-clip (2K1C) rat model. Animals were killed at 1 or 12 weeks after
surgery (acute or chronic RVH). Angiotensin II was quantitated with radioimmunoassay. Angiotensin II–type 1 (AT1)
receptor density was determined with immunoblotting and immunohistochemistry.
Results: Blood pressure was significantly elevated in 2K1C animals compared with sham animals at 1 week (141  5 mm
Hg versus 98  3 mm Hg; P < .0005) and at 12 weeks (164  14 mm Hg versus 110  7 mm Hg; P < .0005) after
surgery. No significant difference was seen in plasma angiotensin II levels between 2K1C and control animals during
acute (38.2  6.5 fmol/mL versus 27.6  6.8 fmol/mL; P  not significant) or chronic (40.1  17.4 fmol/mL versus
27.1 6.5 fmol/mL; P not significant) RVH. During acute RVH, intrarenal angiotensin II was significantly increased
in both the clipped (126.0 16.2 fmol/g versus 62.0 6.2 fmol/g; P < .005) and unclipped (78.9 6.3 fmol/g versus
39.9  2.5 fmol/g; P < .05) kidneys of 2K1C animals compared with control animals. Increased intrarenal angiotensin
II levels persisted in chronic RVH in the clipped (147.4 37.7 fmol/g versus 59.2 8.7 fmol/g; P < .05) and unclipped
(130.8  31.8 fmol/g versus 63.0  11.0 fmol/g; P < .05) kidneys of 2K1C animals compared with controls. Adrenal
angiotensin II content of 2K1C animals was unchanged in acute RVH (493.7  51.4 fmol/g versus 522.6  80.5
fmol/g; P  not significant) but increased nearly three-fold over control animals during chronic RVH (1129.0  149.3
fmol/g versus 400.6  59.1 fmol/g; P < .0005). No significant difference in AT1 receptor density was noted in renal
tubules of clipped and unclipped kidneys or in the adrenal glands of 2K1C animals during acute or chronic RVH
compared with control animals.
Conclusion: Tissue angiotensin II production is upregulated in the kidneys and adrenal glands in chronic RVH, and AT1
receptor density is maintained in these tissues, providing a potential mechanism for maintenance of hypertension in RVH.
(J Vasc Surg 2002;36:386-92.)
Renovascular hypertension (RVH) is postulated to be
the consequence of pathologic activation of the renin-
angiotensin system (RAS) induced by renal artery stenosis.
This assertion is supported by the observation that
angiotensin-converting enzyme (ACE) inhibitors have an-
tihypertensive effects in both clinical and experimental
models of RVH.1-4 Despite evidence suggesting a central
role for the RAS in RVH, plasma levels of the hormone
angiotensin II are not always increased in RVH.5,6 Brown
et al5 showed that patients with long-standing unilateral
RVH may have normal levels of circulating angiotensin II
and that angiotensin II levels do not correlate with blood
pressure (BP). Similarly, the two-kidney one-clip (2K1C)
rat model of experimental RVH is characterized by a
chronic phase of hypertension in which circulating angio-
tensin II returns to normal.5-8 This observation presents a
paradox in which hypertension persists despite normal cir-
culating levels of angiotensin II.
The observation that individual components of the
RAS, such as renin, angiotensinogen, ACE, and the angio-
tensin II–type 1 (AT1) receptor, are expressed in multiple
tissues involved in BP regulation portends the possibility
that angiotensin II may be generated locally by tissue-
specific RAS. Upregulation of gene expression for elements
of the RAS may ultimately permit increased local produc-
tion of angiotensin II and its AT1 receptor, without an
increase in plasma angiotensin II. Increased tissue angio-
tensin II levels in the kidney and adrenal gland may aug-
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ment sodium reabsorption9 and aldosterone release,10 re-
spectively, to increase BP and reconcile the discrepancy
between BP and plasma angiotensin II in clinical RVH. In
support of this notion, our laboratory and others have
shown upregulation of components of the RAS in tissues
involved in BP regulation in RVH.8,11-17 This study exam-
ined the hypothesis that renal artery stenosis upregulates
local angiotensin II levels in the kidneys and adrenal glands
to maintain hypertension in chronic RVH.
METHODS
Animal protocol. The 2K1C model was used to in-
duce experimental RVH. This model is described else-
where.2 The 2K1C model is characterized by three physi-
ologic phases.2 Phase I (0 to 4 weeks) is marked by
increased plasma renin and angiotensin II content and
hypertension. Phase II (5 to 8 weeks) is marked by decreas-
ing plasma renin and angiotensin II, salt retention, and
hypertension. In phase III (9 weeks), hypertension be-
comes renin-independent because both plasma renin and
angiotensin II content return to normal, simulating clinical
RVH.2
Sprague-Dawley rats, weighing 200 to 250 g, were
randomly allocated to two treatment groups: 2K1C and
sham-operated control groups. Noninvasive BP was mea-
sured before surgery and again before death with a tail cuff
photosensor (IITC, Inc, Woodland Hills, Calif). A midline
laparotomy was used for placement of a 0.2-mm (internal
diameter) partially occlusive clip on the left renal artery of
2K1C animals. Control animals underwent laparotomy
without clip placement. Animals were killed at 1 or 12
weeks after surgery, corresponding to acute and chronic
phases of the 2K1C model.2 The study was approved by the
Institutional Animal Care and Use Committee, and animal
care complied with the Guide for the Care and Use of
Laboratory Animals.18
Plasma and tissue angiotensin II assay. Angiotensin
II assays were performed according to the technique of Fox
et al.19 Blood from the infrarenal aorta was collected into a
chilled glass tube containing protease inhibitors (pepstatin
A and 1,10-phenanthroline) and enalapril maleate (Sigma,
St Louis, Mo). Tissues were homogenized in ice-cold
methanol. After clarification with centrifugation, samples
were applied to a phenyl-bonded solid phase extraction
column (Varian, Harbor City, Calif). After elution from the
column with 90% methanol, samples were dried and recon-
stituted for radioimmunoassay. The radioimmunoassay for
angiotensin II was performed according to the technique of
Fox et al,19 with rabbit anti–angiotensin II antibody (Phoe-
nix Pharmaceuticals, Inc, Belmont, Calif), with cross reac-
tivity of less than 2% for angiotensin II precursors and
degradation products. After incubation of the radioimmu-
noassay for 48 hours at 4° C, bound and free angiotensin II
were separated with dextran-coated charcoal. The superna-
tant was counted with a -counter (ICN, Costa Mesa,
Calif). The ratio B/Bo was corrected for nonspecific bind-
ing, expressed as a percentage of maximal binding, and read
against a standard curve (log-logit transformation) with
linear regression.
Kidney brush border membrane isolation. Kidney
tubule brush border membranes (BBMs) were isolated for
determination of AT1 receptor density because this cell type
is most relevant to the kidney’s role in sodium reabsorption
and BP regulation. AT1 receptor expression is differentially
regulated in glomeruli and tubules,20,21 so isolation of
tubule BBMs also circumvents this potential pitfall. BBMs
were isolated with a standard magnesium precipitation
protocol.22 Briefly, superficial renal cortex was homoge-
nized and magnesium precipitated twice with 0.54 mL of 1
mol/L MgCl2 solution in 15 mL H20. Ultracentrifugation
at 39,800g for 36 minutes yielded a BBM pellet for immu-
noblotting.
Adrenal protein preparation for immunoblotting.
Preparation of adrenal protein for immunoblotting was on
the basis of the protocol of Harrison-Bernard et al.20
Briefly, adrenals were homogenized, clarified with centrif-
ugation, and treated with deoxycholate (0.05% weight/
volume, 30 minutes). A pellet was obtained with centrifu-
gation at 20,000g for 30 minutes at 4° C.
Immunoblotting. Multiple approaches were used for
quantitation of AT1 receptor density in renal tubules and
adrenal glands. Radioligand binding is often used for de-
termination of receptor density. However, binding assays
with 125I–angiotensin II consistently yielded high nonspe-
cific binding that precluded reliable quantitation of AT1
receptor density with this technique. Therefore, immuno-
blotting was used to quantitate AT1 receptor density.
Twenty-microgram samples were boiled for 5 minutes
and separated with gel electrophoresis on 10% polyacryl-
amide gels. Appropriate negative controls were included.
Gels were transferred to nitrocellulose, blocked with
blotto, and reacted with rabbit anti-AT1 receptor primary
antibody (Santa Cruz Biotechnology, Inc, Santa Cruz,
Calif) overnight at 4° C. Goat antirabbit secondary anti-
body (Research Diagnostics, Inc, Flanders, NJ) was added
for 2 hours. Signal was visualized with enhanced chemilu-
minescence (Pierce, Rockford, Ill) and quantitated with
densitometry (Biorad, Hercules, Calif).
Perfusion fixation and immunohistochemistry.
Perfusion fixation of tissues was described previously.23
After perfusion fixation with 3% paraformaldehyde, 0.1
mol/L cacodylic acid/sucrose buffer, 4% pentastarch, 3
mmol/L MgCl2, and 0.05% picric acid, tissues were im-
mersed in formalin for paraffin embedding. Sections were
treated with target retrieval solution (DAKO, Carpenteria,
Calif), quenched with 3% hydrogen peroxide, and blocked
with avidin/biotin blocking solution (Vector, Burlingame,
Calif) before staining with rabbit anti-AT1 receptor primary
antibody (Santa Cruz Biotechnology) overnight at 4° C.
No cross reactivity of the anti- AT1 receptor primary anti-
body with the AT2 receptor was seen. Slides were treated
with biotinylated goat antirabbit secondary antibody (Vec-
tor) for 1 hour and stained with streptavidin peroxidase
(DAKO) before signal amplification with biotinylated
tyrimide (TSA Kit, NEN Life Science, Boston, Mass).
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Staining was detected with diaminobenzidine (Vector).
Appropriate negative control slides (no primary antibody)
were included in each experiment. Antibody specificity was
confirmed with blocking with a 100-fold excess of AT1
receptor peptide. Slides were reviewed in a blinded manner
by a renal pathologist (TER) who examined multiple high-
power fields on each slide. Staining of the BBM was graded
on a scale from 0 to 3. A score of 0 was given for slides
with no staining, 1 for minimal staining, 2 for moderate
staining, and 3 for intense staining at the BBM.
Statistical methods. Sample size was determined with
power analysis. Ten animals per group were necesary to
achieve a power of 0.8 for angiotensin II assays at a signif-
icance level of 0.05. Continuous data were expressed as the
mean  the standard error of the mean and compared
between groups with an unpaired two-tailed Student t test.
A P value of less than .05 defined statistical significance.
RESULTS
Morphometric and blood pressure data. Control
and 2K1C animals showed no significant difference in body
weight or BP before surgery or before death (data not
shown). Hypertension developed in 2K1C animals by 1
week after surgery (P  .0005; Fig 1, A) and persisted
during chronic RVH (P .0005; Fig 1, B) compared with
control animals. Weight of clipped and unclipped kidneys
was not significantly different between 2K1C and control
animals at 1 week after surgery (data not shown). By 12
weeks after surgery, a significant increase in renal mass was
noted in the unclipped kidney of 2K1C animals compared
with control animals (P  .05; Fig 2, B, online only). No
significant difference was seen in mean weight of the
clipped kidney of 2K1C and control animalss at 12 weeks
after surgery (P not significant; Fig 2, A, online only). A
significant increase was seen in the mean ratio of kidney
weights (unclipped/clipped) in chronic 2K1C animals
(1.23  0.05) compared with control animals (0.99 
0.01; P  .001).
Plasma and tissue angiotensin II. For determination
of whether plasma angiotensin II is upregulated in either
the acute or chronic RVH, animals were killed at 1 week or
12 weeks after surgery for quantitation of plasma angioten-
sin II. Despite significant hypertension in 2K1C animals,
no significant difference was seen in plasma angiotensin II
levels between 2K1C and control animals during acute
RVH (Fig 3, A). A similar pattern of plasma angiotensin II
was observed in chronic RVH (Fig 3, B); the plasma
angiotensin II levels of 2K1C animals were not significantly
different from control animals.
For determination of whether renal artery stenosis up-
regulates local RAS in tissues involved in BP regulation,
angiotensin II was extracted from the kidneys of 2K1C
animals. During acute RVH, intrarenal angiotensin II of
the clipped kidney was increased two-fold in 2K1C animals
compared with control animals (P  .005; Fig 4, A).
Interestingly, a similar pattern was observed in the con-
tralateral unclipped kidney of 2K1C animals compared with
Fig 1. A, Mean systolic BP (mm Hg) 1 week after surgery for 2K1C (n  12) and control (n  12) animals (*P 
.0005). B, Mean systolic BP (mm Hg) 10 weeks after surgery for 2K1C (n 12) and control (n 12) animals (*P
.0005).
Fig 3. A, Mean plasma angiotensin II (fmol/mL) at 1 week after surgery for 2K1C (n  11) and control (n  10)
animals (P not significant). B, Mean plasma angiotensin II (fmol/mL) 12 weeks after surgery for 2K1C (n 12) and
control (n  12) animals (P  not significant).
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control animals (P  .05; Fig 4, B). The difference in
intrarenal angiotensin II levels between 2K1C and control
animals persisted in chronic RVH (Fig 5). At 12 weeks after
surgery, intrarenal angiotensin II levels remained elevated
in the clipped kidney of 2K1C animals (P .05; Fig 5, A).
The unclipped kidney of 2K1C animals showed a similar
increase in intrarenal angiotensin II content compared with
control animals (P  .05; Fig 5, B).
Because local angiotensin II levels in the adrenal gland
are a known stimulant for induction of aldosterone produc-
tion and secretion,10 the angiotensin II content of the
adrenal glands of 2K1C animals was examined (Fig 6). At 1
week after surgery, no difference was seen in adrenal angio-
tensin II content between 2K1C and control animals (Fig
6, A). However, adrenal angiotensin II content of 2K1C
animals was increased nearly three-fold over control ani-
mals at 12 weeks (P  .0005; Fig 6, B). For determination
of which of the adrenal glands was responsible for the
observed upregulation of adrenal angiotensin II content in
2K1C animals, left and right adrenal glands of chronic
RVH animals were processed separately and compared for
angiotensin II content. The angiotensin II content of both
adrenal glands of 2K1C animals was upregulated equally
compared with control rats (data not shown).
Fig 4. A, Mean intrarenal angiotensin II (fmol/g) in clipped kidney 1 week after surgery for 2K1C (n  12) and
control (n  12) animals (*P  .005). B, Mean intrarenal angiotensin II (fmol/g) in unclipped kidney 1 week after
surgery for 2K1C (n  12) and control (n  12) animals (**P  .05).
Fig 5. A, Mean intrarenal angiotensin II (fmol/g) in clipped kidney 12 weeks after surgery for 2K1C (n  12) and
control (n  12) animals (*P  .05). B, Mean intrarenal angiotensin II (fmol/g) in unclipped kidney 12 weeks after
surgery for 2K1C (n  12) and control (n  12) animals (*P  .05).
Fig 6. A, Mean adrenal angiotensin II (fmol/g) 1 week after surgery for 2K1C (n 12) and control (n 12) animals
(P not significant). B, Mean adrenal angiotensin II (fmol/g) 12 weeks after surgery for 2K1C (n 12) and control
(n  12) animals (*P  .0005).
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Angiotensin II–type 1 receptor density. During
acute RVH, no significant difference in AT1 receptor pro-
tein was noted with immunoblotting of renal tubule BBMs
from clipped and unclipped kidneys of 2K1C animals com-
pared with control animals (data not shown). During
chronic RVH, both clipped (Fig 7, B) and unclipped (Fig 7,
A) kidneys showed no significant difference in AT1 recep-
tor density between 2K1C and control animals. A similar
pattern of AT1 receptor density was noted in the adrenal
glands; no detectable difference in AT1 receptor density
was observed between 2K1C and control animals at 1 or 12
weeks after surgery (data not shown).
Immunohistochemistry for AT1 receptor density cor-
roborated the immunoblotting data. No difference in BBM
staining for the AT1 receptor was observed in clipped and
unclipped kidneys of 2K1C (n  4) and control (n  4)
animals during acute (data not shown) or chronic (Fig 8,
online only) RVH. Furthermore, no difference in AT1
receptor staining was noted in the adrenal glands of acute
and chronic 2K1C animals (n  4) compared with control
animals (n  4; data not shown).
DISCUSSION
This study showed marked upregulation of local RAS in
tissues involved in BP regulation in a 2K1C model of
chronic RVH. During both acute and chronic RVH, no
significant increase was seen in plasma angiotensin II. In
contrast, tissue angiotensin II content was markedly up-
regulated in both the clipped kidney and the unclipped
kidney of both acute and chronic 2K1C animals. In addi-
tion, adrenal angiotensin II content was augmented during
chronic RVH. These observations confirm that local RAS
are upregulated in RVH, providing a potential explanation
for the persistence of hypertension in RVH despite a lack of
increased plasma angiotensin II.
The mechanism by which chronic hypertension is
maintained in RVH is poorly understood. Several investi-
gators have noted that activation of the systemic RAS
cannot fully explain the maintenance of hypertension in
chronic RVH.5-7,13 In fact, plasma levels of renin and
angiotensin II are not always increased in RVH.5-7 Plasma
angiotensin II may be unchanged or increased in the acute
phase of the 2K1C model but is certainly not significantly
elevated in the chronic phase of the 2K1C model or clinical
RVH.24-26 To reconcile the dissociation between plasma
angiotensin II content and BP in chronic RVH, our labo-
ratory hypothesized that local angiotensin II production is
upregulated in tissues involved in BP regulation.14-17 To
date, most investigators have attempted to deduce the
activity of local RAS by examining expression of its compo-
nents, such as renin, ACE, and angiotensinogen.11-17 This
approach is predicated on the notion that differential ex-
pression of components of the RAS could provide a means
of increasing local production of angiotensin II. However,
examination of expression of components of the local RAS
in RVH is a surrogate measure of angiotensin II content
in the tissues examined. Posttranslational regulation of
protein expression of RAS components may influence
local biosynthesis of angiotensin II. In addition, receptor-
mediated accumulation of circulating angiotensin II in
tissues may augment local biosynthesis to increase local
angiotensin II activity.27 Hence, direct measurement of
tissue angiotensin II content, as performed in this study, is
essential to examination of the activity of the local RAS in
RVH.
Only rarely have investigators attempted to directly
measure tissue angiotensin II content in RVH, and even
fewer studies have measured angiotensin II in the clinically
relevant chronic phase of the 2K1C model. Guan et al24
found that the angiotensin II content of the unclipped
kidney is elevated during the acute phase of 2K1C hyper-
tension, despite normal plasma angiotensin II content and
depressed renin messenger RNA (mRNA). Before this
Fig 7. Immunoblot for AT1 receptor protein (49 kDa) of BBMs
from either unclipped (A) or clipped (B) kidneys of 2K1C and
control animals at 12 weeks after surgery. Densitometry data for
respective treatment groups (n 12/group) are depicted (P not
significant).
JOURNAL OF VASCULAR SURGERY
August 2002390 Sadjadi et al
study, however, no studies had examined kidney angioten-
sin II content during chronic 2K1C hypertension, which
most closely simulates clinical RVH. Morishita et al17
found that brain and adrenal angiotensin II levels were
unchanged in chronic RVH. This study found that adrenal
angiotensin II levels were increased in chronic RVH. This
discrepancy may be attributed to a difference in technique
for isolation and quantitation of tissue angiotensin II con-
tent. This study used a protocol shown by Fox et al19 to be
least prone to artifactual changes in tissue angiotensin II
levels. Thus, the findings of this study provide the most
direct evidence to date of upregulation of local RAS in the
kidneys and adrenal glands of 2K1C rats in chronic RVH.
This study also addressed the role of the AT1 receptor
in RVH. Without sufficient expression of the AT1 receptor,
increased tissue angiotensin II is of dubious consequence.
Many cell types, such as vascular smooth muscle cells and
adrenal fasciculata cells,28,29 respond to prolonged agonist
stimulation by downregulating AT1 receptors. If normal or
increased AT1 receptor density is observed despite pro-
longed agonist exposure, pathologic activation of the RAS
may ensue.11,20 Consequently, expression of the AT1 re-
ceptor may be a key determinant of whether homeostasis is
maintained or hypertension persists.
For determination of the level of AT1 receptor expres-
sion in RVH, prior studies quantitated AT1 receptor
mRNA levels in RVH.11,14 Haefliger et al14 noted a de-
crease in AT1 mRNA in both kidneys during acute experi-
mental RVH. In contrast, our laboratory found increased
AT1 receptor mRNA levels in both the clipped and un-
clipped kidneys during chronic RVH.11 This study is the
first to directly measure AT1 receptor protein in the kidneys
and adrenal glands of animals with RVH. AT1 receptor
protein abundance, as measured with immunoblotting and
immunohistochemistry, was unchanged in both kidneys
and adrenal glands of 2K1C animals during acute and
chronic RVH. However, the semiquantitative techniques
of immunoblotting and immunohistochemistry possibly
may not detect minor changes in AT1 receptor density. The
discrepancy between mRNA and protein abundance may
be a product of posttranslational regulation of AT1 receptor
protein expression or the result of the different fractions of
the kidney examined (whole kidney homogenates versus
BBMs in this study). Maintenance of AT1 receptor expres-
sion, without downregulation of receptor numbers, is rel-
evant to the pathogenesis of RVH. In the context of
increased tissue angiotensin II content, this level of AT1
receptor expression provides a mechanism for sustained
signaling and physiologic effects to augment BP.
Upregulation of angiotensin II and maintenance of
AT1 receptor expression in the chronic phase of experimen-
tal RVH is consistent with the known pathophysiology of
the 2K1C model.2 As RVH evolves in this model, hyper-
tension becomes progressively more renin-independent be-
cause both plasma renin and angiotensin II return to nor-
mal in the chronic phase of the model. Concurrently, 2K1C
hypertension evolves into the volume hypertension that
characterizes clinical RVH. Because intrarenal angiotensin
II is known to augment tubular sodium reabsorption in
normotensive and 2K1C rats,9 the observation that chronic
2K1C rats have increased intrarenal angiotensin II levels in
both kidneys is particularly relevant to the evolution of
volume hypertension in RVH. Increased adrenal angioten-
sin II is known to stimulate aldosterone secretion,10 so our
demonstration of increased adrenal angiotensin II levels in
2K1C animals provides a mechanism for aldosterone re-
lease despite normal plasma angiotensin II. Taken together,
our findings provide a mechanism for promoting volume
retention and hypertension in RVH.
Although increased tissue angiotensin II in the kidneys
and adrenal glands of 2K1C animals is presumed to lead to
hypertension, a limitation of this study is its inability to
directly establish a causal relationship between increased
tissue angiotensin II and hypertension. Standard ap-
proaches to showing causality, such as blockade of the RAS
during RVH, are problematic because ACE inhibitors af-
fect both the systemic RAS and local RAS. Such a global
effect on angiotensin II production would preclude any
determination regarding the pathogenetic role of tissue-
specific RAS in maintaining hypertension in chronic RVH.
Future studies will likely require the use of alternative
approaches, such as gene delivery of antisense DNA, to
block the local RAS of specific organs to determine their
pathogenetic role in RVH.
This study cannot exclude alternative scenarios involv-
ing interactions between the systemic RAS and local RAS.
Plasma renin activity was not measured, and a previous
report noted that plasma renin activity may be increased in
rats during chronic RVH.30 Thus, this study cannot ex-
clude the possibility that renin may be synthesized in the
ischemic kidney, released into the plasma, and transported
to the nonischemic kidney and adrenal glands. After arriv-
ing in these tissues, renin could convert angiotensinogen to
angiotensin I. This scenario would require activation of
tissue RAS because plasma ACE activity is not increased in
2K1C hypertension and tissue ACE activity is upregulated
in both the clipped and unclipped kidneys of 2K1C ani-
mals.
This study raises additional questions regarding activa-
tion of local RAS. How the local RAS of the unclipped
kidney and adrenal glands are activated in RVH remains
unclear from this study. Recent reports suggest that small
incremental increases in plasma angiotensin II, such as that
observed in RVH, may have profound affects on tissue
angiotensin II levels in distant organs.27,31,32 Such in-
creases in tissue angiotensin II could not be explained with
“trapping” of plasma in these organs because the concen-
tration of angiotensin II in the kidney and adrenal glands
are several-fold higher than plasma angiotensin II concen-
tration. Instead, small incremental increases in plasma an-
giotensin II likely activate local RAS to induce angiotensin
II production in the unclipped kidney and adrenal glands.
Increased tissue angiotensin II could then act in an
autocrine-paracrine fashion to increase BP. Careful deduc-
tion of the complex interactions between local and systemic
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RAS will be critical to understanding the mechanisms by
which hypertension is maintained in RVH.
In summary, this study confirmed that local RAS are
upregulated in the kidneys and adrenals of chronic RVH
animals. In addition, AT1 receptor expression was main-
tained in proximal tubules and adrenal glands despite in-
creased local angiotensin II content. These data provide a
means by which increased tissue angiotensin II may aug-
ment BP. The mechanism by which such local RAS are
activated remains unknown. Decreased perfusion pressure
at the juxtaglomerular apparatus may activate the ischemic
kidney’s RAS, but how the local RAS of the nonischemic
kidney and adrenal glands are subsequently activated is not
known. Despite the questions that remain, this study offers
further insight into the pathogenesis of RVH.
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